Tissue Regenix Reports Strong First Half as it Focuses on Four Growth Pillars

Building on the Success of its Orthopaedics Business, the Company Expects to Report Further Growth in 2023

Tissue Regenix, a leading medical technology company, has reported strong financial results for the first half of 2023. The company's revenue grew by 22% year-on-year, driven by continued strong demand for its orthopaedics products.

Tissue Regenix's orthopaedics business continued its strong performance, with revenue growth of 25%. This growth was driven by the successful launch of a number of new products, as well as increased demand for the company's existing portfolio.

Diversification into New Markets

Tissue Regenix is also making progress in diversifying its business into new markets. The company's regenerative medicine business continues to grow, with a number of new clinical trials underway. The company is also exploring opportunities in the wound care and sports medicine markets. Tissue Regenix is expecting to report further growth in 2023 as it continues to focus on its four growth pillars: expanding its orthopaedics business, investing in regenerative medicine, diversifying into new markets, and acquiring complementary businesses. The company's strong financial performance and growth prospects make it an attractive investment for investors looking for a long-term play in the medical technology sector.

About Tissue Regenix

Tissue Regenix is a leading medical technology company that develops, manufactures, and markets a range of orthopaedic and regenerative medicine products. The company's products are used to treat a variety of conditions, including osteoarthritis, cartilage defects, and fractures. Tissue Regenix has a strong track record of innovation and has a number of new products in development. The company is headquartered in the UK and has operations in the US and Europe.